Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing treatments for rare, life-altering liver diseases. Founded in 2014 and headquartered in Foster City, California, the company focuses on developing innovative therapies that address gastrointestinal and hepatic disorders with significant unmet medical needs. Mirum’s research and clinical efforts are centered on improving quality of life for patients suffering from chronic cholestatic conditions by targeting the underlying mechanisms of bile acid transport and metabolism.
The company’s lead product, maralixibat (branded as Livmarli™), is an orally administered ileal bile acid transporter (IBAT) inhibitor designed to alleviate pruritus and other cholestasis-related symptoms in patients with Alagille syndrome. In 2021, Livmarli received approval from the U.S. Food and Drug Administration, marking a milestone as the first treatment approved for cholestatic pruritus in pediatric patients with Alagille syndrome. Mirum has also advanced clinical programs for other rare liver disorders, including progressive familial intrahepatic cholestasis (PFIC) and primary sclerosing cholangitis (PSC), evaluating maralixibat’s broader therapeutic potential.
Mirum’s commercial and clinical operations span North America, Europe and select international markets. Following regulatory approvals, the company has launched specialty distribution networks, engaged with healthcare providers and collaborated with patient advocacy groups to facilitate access to its therapies. Clinical trial sites are established in the United States, Europe and Australia, reflecting Mirum’s commitment to global patient populations affected by debilitating cholestatic diseases.
Under the leadership of Chief Executive Officer David Rodnick, Mirum has assembled a team of experienced executives and scientific advisors with deep expertise in hepatology, gastroenterology and rare disease drug development. The company’s board and management leverage backgrounds in regulatory affairs, clinical operations and commercial strategy to navigate the complexities of orphan drug development. Mirum maintains partnerships with academic institutions and research organizations to support ongoing innovation and expand its pipeline, with a vision to transform care for patients with rare liver conditions.
AI Generated. May Contain Errors.
Free MIRM Stock Alerts